Chinese Medicine's Intervention Effect on Nogo-A/NgR by Qin, Xiu-de et al.
Hindawi Publishing Corporation
Evidence-Based Complementary and Alternative Medicine
Volume 2012, Article ID 528482, 4 pages
doi:10.1155/2012/528482
Review Article
ChineseMedicine’sIntervention Effecton Nogo-A/NgR
Xiu-de Qin,1 Li-yuanKang,1 Yu Liu,2 Yan Huang,3 ShuoWang,1 andJin-qiangZhu1
1Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No. 312 Anshanxi Road,
Nankai District, Tianjin 300193, China
2The Second Clinical Medical School, Guangzhou University of Chinese Medicine, Guangzhou 510405, China
3Encephalopathy Center, Guangdong Hospital of TCM, Guangzhou 510120, China
Correspondence should be addressed to Li-yuan Kang, klyzm@163.com
Received 15 June 2011; Revised 28 September 2011; Accepted 2 November 2011
Academic Editor: Carlo Ventura
Copyright © 2012 Xiu-de Qin et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cerebral vascular disease is very common in the elderly and is one of the most dangerous diseases which is hazardous to the body’s
health, and it is the medical specialists’ study hot spot not only in the clinical ﬁeld but also in the medical basic research ﬁeld.
Neural regeneration has been paid more and more attention in recent years. Nogo’s function in the process of neural regeneration
has become the focal point since it was discovered in the year 2000. Many studies elucidate that Nogo negatively aﬀects the neural
regeneration and plasticity. Chinese medicine plays an important role in the prevention and treatment of neural diseases, and
recently some researches about the Chinese medicine’s intervention eﬀect on Nogo-A/NgR sprang up, so it is necessary to make a
review on this aspect.
1. Nogo’s Discovery
That Nogo gene was successfully cloned in 2000 is one of the
mostimperativebreakthroughssincetheneuralregeneration
inhibitors’ discovery. The Nogo isoforms A, B, and C are
members of the reticulon family of proteins. Nogo-A and
Nogo-C are highly expressed in the central nervous system,
with Nogo-C being additionally found in skeletal muscle,
whereas Nogo-B is found in most tissues. Of the three major
isoforms of Nogo, Nogo-A is the most intense inhibitor of
neural regeneration in central nervous system. It can inhibit
axonal growth both in vitro and in vivo, remarkably [1, 2].
2. Nogo-A/NgR’s Distribution
2.1. Nogo-A/NgR’s Distribution in the Body. Nogo-A/NgR is
widely distributed in the nervous system, but seldomly in the
viscus. In human fetal tissue, Nogo-A is strongly expressed
in the two-thirds of the ventral of the spinal cord, the dorsal
root ganglia, and autonomic ganglia. Similarly, Nogo-A
mRNAexpressionisobservedintheadulthumanspinalcord
and ganglia. High levels of Nogo-A message are observed
in motor neurons and sensory ganglia neurons. In addition,
expression of Nogo-A mRNA is observed in developing mu-
scle tissue. In fetal rats, the adrenal gland and cell clusters
in the liver were positive for the Nogo-ABC pan-probe, but
negative for the Nogo-A probe [3]. Throughout much of
t h ea d u l tc e n t r a ln e r v o u ss y s t e m( C N S ) ,N o g o - Ai sd e t e c t e d
in oligodendrocyte processes surrounding myelinated axons,
including areas of axon-oligodendrocyte contact. Nogo-A
receptor (NgR) expression is restricted to postnatal neurons
andtheiraxons.Incontrast,Nogo-Aisobservedinmyelinat-
ing oligodendrocytes, embryonic muscle, and neurons. After
spinal cord is injured, Nogo-A is upregulated to a moderate
degree, whereas NgR levels are maintained at constant levels.
Taken together, these data conﬁrm the apposition of Nogo
ligand and NgR in situations of limited axonal regeneration
and support the hypothesis that this system regulates CNS
axonal plasticity and recovery from injury [4].
2.2. Nogo-A/NgR’s Distribution in the Brain. Study indicated
that neurons in the adult rat brain were generally positive,
and very prominent nogo-A mRNA and nogo-ABC mRNA
signals were obtained from neurons of the hippocampus,
piriform cortex, the red nucleus, and the oculomotor nu-
c l e u s .N o g om R N Aw a se x p r e s s e di nn e u r o n sa n do l i g o d e n -
drocytes, but not astrocytes or Schwann cells [3]. In situ
hybridization method was used to investigate the expression
of mRNA for NgR in unoperated adult rats and mice.
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hippocampal formation, amygdaloid nuclei, and dorsal
thalamus and moderately expressed in the red nucleus and
vestibular nuclei. NgR mRNA was expressed in cerebellar
deep nuclei and more strongly in granule cells than in
Purkinje cells. Large regions of the forebrain, including the
striatum, thalamic reticular nucleus, hypothalamus, and
basal forebrain showed little or no NgR expression. Nerve
implantation into the brain did not aﬀect NgR expression.
Some regeneration-competent neurons expressed NgR but
others did not. Nogo-66 transcripts were strongly expressed
in many classes of CNS neurons and less strongly in white
matter [5].
3. Nogo-A/NgR’s Biological Function
andAdhibition
3.1. Nogo-A/NgR’s Main Biological Function. Nogo-A/NgR’s
function has been extensively explored in recent years, and
their main physiological function is believed to be maintain-
ing the stabilization of nervous system and regulating the
plastic rearrangements and regeneration after neural injury.
An interaction of Nogo on the oligodendrocyte surface with
NgR on axons has been suggested to play an important role
in limiting axonal growth [4]. Nogo-A and NgR are potent
neuritegrowthinhibitorsinvitroandplayaroleininhibition
of axonal regeneration following injury and central nervous
system structural plasticity in vertebrates [6, 7]. The role of
Nogo-Ainlimitingaxonalﬁbergrowthandregenerationfol-
lowing the injury of the mammalian CNS is well known, The
present results show a unique role of Nogo-A expressed in
the adult hippocampus in restricting physiological synaptic
plasticityonaveryfasttimescale.Nogo-Acouldthusserveas
an important negative regulator of functional and structural
plasticity in mature neuronal networks [8]. Nogo-A plays a
major role in stabilizing and maintaining the architecture
of hippocampal pyramidal neurons; although the majority
of the activity of Nogo-A relies on a receptor-mediated
mechanism involving NgR1, its cell-autonomous function
plays a minor role [9]. Nogo could aﬀect memory ability
throughregulatingsynapseremodeling.Nogo-Aispresentin
inhibitory presynaptic terminals in cerebellar Purkinje cells
at the time of Purkinje cell-deep cerebellar nuclei inhibitory
synapseformationandisthendownregulatedduringsynapse
maturation [10]. NgR1 participates in ligand-dependent
inhibition of synaptic plasticity. Loss of NgR1 leads to
increased phosphorylation of extracellular signal-regulated
kinase 1/2, signaling intermediates known to regulate neu-
ronal growth and synaptic function [11]. NgR might have
wider eﬀects on inﬂammation in a variety of neurological
conditions ranging from central nervous system trauma to
diseasessuchasmultiplesclerosisorAlzheimer’sdisease[12].
3.2. Main Studies of the Adhibition of Nogo-A/NgR
in Neural Disease
3.2.1. In Neurological Deﬁcits. One study indicated that
improvement of chronic neurological deﬁcits and enhance-
ment of neuronal plasticity can be induced in the adult rat
with anti-Nogo-A immunotherapy, and that this therapy
maybeusedtorestorefunctionevenwhenadministeredlong
after ischemic brain damage has occurred [13]. Karl´ en et al.’s
experiment showed that mice with inducible overexpression
of NgR1 in forebrain neurons have normal long-term
potentiationandnormal24hmemory,butseverelyimpaired
month-long memory in both passive avoidance and swim
maze tests, while blocking transgene expression normalizes
the memory impairments [14].
3.2.2. In Cerebral Ischemia. Blocking or refraining Nogo-A
pathway has displayed promising eﬀect on cerebral ischemia.
Wiessner et al. [15] used monoclonal anti-Nogo-A antibody
(7B12) to treat cerebral ischemia rats successfully and con-
sideredthatspeciﬁcanti-Nogo-Aantibodiesbearpotentialas
a new rehabilitative treatment approach for ischemic stroke
with a prolonged time-to-treatment window. Chun-Mei et
al.’s study [16] indicated that scalp site medication injection
could stimulate endogenous neural stem cells proliferation
and promote their diﬀerentiation and also could inhibit the
expression of the nerve regeneration inhibitory factor Nogo-
A in brain, there by promoting the repair of brain.
3.2.3. In Traumatic Brain Injury. Functional recovery is
markedly restricted following traumatic brain injury (TBI),
partlyduetomyelin-associatedinhibitorsincludingNogo-A,
myelin-associated glycoprotein, and oligodendrocyte myelin
glycoprotein, which are all bound to the NgR1. H˚ anell et al.’s
studyindicatedthatcognitivefunction(asevaluatedwiththe
Morris water maze at 4 weeks after injury) was signiﬁcantly
impaired both in NgR1 −/− mice and in mice treated
with soluble NgR1. In the sNgR1 study, they evaluated
hippocampal mossy ﬁber sprouting using the Timm stain
and found it to be increased at 5 weeks following TBI.
Neutralization of NgR1 signiﬁcantly increased mossy ﬁber
sprouting in sham-injured animals, but not in brain-injured
animals. And their study urge caution when inhibiting NgR1
in the TBI’s early post injury period [17].
3.2.4. In Injured Spinal Cord. Nogo-neutralizing antibody
IN-1 increases c-Jun protein levels and protects the injured
spinal cord by inhibiting c-Fos protein levels. Moreover,
the eﬀects of IN-1 combined with neurotrophin-3 are more
signiﬁcant than with IN-1 alone [18].
3.2.5. In Alzheimer Disease. Nogo-A upregulation and Nogo
receptor downregulation in AD rats have relationship with
the pathological changes. The estrogen can normalize the
expressions of Nogo-A and Nogo receptor so that estrogen
can protect neurons from damages. The mechanism of
Nogo-A upregulation and Nogo receptor downregulation
induced by estrogen in AD models needs to be further
researched. Nogo-A and Nogo receptor are presumed to be
involved in the pathological processes of AD [19].
4. Chinese Medicine’sInterventionon
Nogo-A/NgR
4.1. In Cerebral Ischemia. Studies have manifested that some
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through regulating the expression of Nogo-A. Huai-Qiang
et al.’s study [20] indicated that Nogo-A expression was
observed at a short period after cerebral infarction in the
model group and increased gradually, reaching a peak at
2 weeks and was still positive at 6 weeks after infarction.
The diﬀerences between model and normal control groups
were signiﬁcant at the same stage (P<0.01). The diﬀerence
between Fujian tablet group and model group was not
signiﬁcant (P>0.05) at 3 days, but signiﬁcant (P<0.01)
at other stages; thus demonstrating that Fujian tablet can
promote neurogenesis by inhibiting the expression of Nogo-
A. Fujian tablet could also inhibit the expression of Nogo-
A mRNA in cervical spinal cords of middle cerebral artery
occlusion (MCAO) rats, which facilitates regeneration and
remodeling of cervical spinal cords [21]. The number of
Nogo-A-immunoreactive cells at the 3rd day after reperfu-
sioninpanaxtrialsaponins(PTS)groupdecreasedcompared
with the placebo group (P>0.05). And the number at the
7th day in PTS group decreased markedly and represented
signiﬁcant diﬀerence compared with the placebo group (P<
0.05). This study implies that PTS could downregulate the
expression of Nogo-A, and it might be one of the protective
mechanisms of PTS against ischemia-reperfusion injury
[22]. Wen-Tao et al. duplicated chronic ischemic mice model
and observed the butylphthalide’s intervention eﬀect on the
expression of Nogo-A; they found that the expression of
Nogo-A in the low dose and high-dose especially high-dose
butylphthalide group was obviously reduced than the model
group, thus indicating that butylphthalide’s protective eﬀect
on chronic ischemic is probably through downregulating the
expression of Nogo-A [23]. Wang’s experiment manifested
that compound Shouwuxianhai tablet could remarkable
restrain the Nogo-A expression in MCAO rat brain, there-
from promoted the neural regeneration after ischemic stroke
[24].
4.2. In Hypoxic-Ischemic Brain Damage. Altered Nogo-A
expression was associated with inversely altered synapto-
physin expression. The use of ephedrine normalized expres-
sion levels of Nogo-A and synaptophysin following hypoxic-
ischemic brain damage (HIBD). Chen et al.’s study demon-
strated that Nogo-A expression was signiﬁcantly reduced in
the ephedrine group compared with the HIBD group (P<
0.01). Synaptophysin expression was signiﬁcantly decreased
in the hypoxic-ischemic cortex, compared with the sham
operation group (P<0.01). Synaptophysin levels were
signiﬁcantly increased in the ephedrine group, compared
with the HIBD group (P<0.01) [25].
4.3. In Situation of Injured Spinal Cord. Chinese Medicine
Sui fukang (SFK) is possible to improve microenvironment
in the injured spinal cord and to make nervous tissue
regenerate through restraining the expression of Nogo-A.
Animal experiment indicated that the positive cells of
Nogo-A mRNA were more and their OD value was higher
in the model group than those in other groups (P<0.05);
the Nogo-A mRNA positive cells were less and their OD
value was lower in SFK group than those in the model group
(P<0.05). The changes of Nogo-A protein positive cells
number and its OD value were similar with those of Nogo-A
mRNA [26].
5. Problem and Prospect
Neuroscience has stepped forward a lot for the past few
years, and more and more attention is paid to the neuro
regeneration and neuroremodeling. As one of the most
intensive neuroregeneration inhibitors, Nogo-A has been
focused on a lot since it was discovered. Many ways related to
Nogo-A were used to promote the regeneration of neurons
in neural disease, such as Nogo’s inhibitor, Nogo’ antibody,
knockout of Nogo gene, and any other possible medication
which could refrain the expression of Nogo.
Stroke and dementia are closely associated, whether in
the form of vascular cognitive impairment or Alzheimer’s
disease. At least 35 million people worldwide currently have
dementia. Dementia prevalence is predicted to double every
20 years: an expected 66 million in 2030 and 115 million
in 2050. The burden of these diseases is considerable when
taken with the annual 15 million people worldwide who will
suﬀer stroke [27]. It is well known that Chinese medicine
could take eﬀect through multiple target points, and it is
believed that Chinese medicine has good eﬀect on neural
diseases, especially on the treatment of stroke, dementia,
and other chronic neural degeneration diseases. There are
already some well-known Chinese medicine agents which
have potential good therapeutic eﬀect on stroke or dementia
patients, such as Ginkgo Biloba extract, Lamps spend grain
injection, and Huperzine A. Chairman MAO once said:
“Chinese medicine is a great treasure and we should make
eﬀort to explore it well”, so the step of developing more
eﬀective Chinese patent drug from Chinese medicine should
never stop, and whether are there any Chinese medicine
which could take eﬀect on stroke or dementia through
regulating the Nogo-A/NgR level or signal transduction
pathway should be further studied.
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